Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung CancerBusiness Wire • 06/03/24
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)Business Wire • 06/02/24
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual MeetingBusiness Wire • 05/23/24
Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to DeclineZacks Investment Research • 04/25/24
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial ResultsBusiness Wire • 04/18/24
Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/22/24
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast CancerBusiness Wire • 03/20/24
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire • 02/29/24
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?Zacks Investment Research • 02/27/24
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care ConferenceBusiness Wire • 02/22/24
Puma Biotech (PBYI) Is Up 23.01% in One Week: What You Should KnowZacks Investment Research • 02/21/24
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire • 02/15/24
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung CancerBusiness Wire • 02/13/24